Search Results - (Author, Cooperation:U. A. Matulonis)
-
1Latest Papers from Table of Contents or Articles in PressT. Ni Chonghaile ; K. A. Sarosiek ; T. T. Vo ; J. A. Ryan ; A. Tammareddi ; G. Moore Vdel ; J. Deng ; K. C. Anderson ; P. Richardson ; Y. T. Tai ; C. S. Mitsiades ; U. A. Matulonis ; R. Drapkin ; R. Stone ; D. J. Deangelo ; D. J. McConkey ; S. E. Sallan ; L. Silverman ; M. S. Hirsch ; D. R. Carrasco ; A. Letai
American Association for the Advancement of Science (AAAS)
Published 2011Staff ViewPublication Date: 2011-10-29Publisher: American Association for the Advancement of Science (AAAS)Print ISSN: 0036-8075Electronic ISSN: 1095-9203Topics: BiologyChemistry and PharmacologyComputer ScienceMedicineNatural Sciences in GeneralPhysicsKeywords: Adult ; Aged ; Animals ; Antineoplastic Agents/*therapeutic use ; *Apoptosis ; Cell Line, Tumor ; Cell Proliferation ; Child ; Disease-Free Survival ; Drug Resistance, Neoplasm ; Female ; Humans ; Leukemia, Myeloid, Acute/drug therapy/physiopathology ; Male ; Membrane Potential, Mitochondrial ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Mitochondria/*physiology ; Multiple Myeloma/drug therapy/physiopathology ; Neoplasms/*drug therapy/*physiopathology ; Ovarian Neoplasms/drug therapy/physiopathology ; Peptide Fragments/metabolism ; Permeability ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/physiopathology ; Proto-Oncogene Proteins c-bcl-2/chemistry/metabolism ; Remission Induction ; Signal TransductionPublished by: -
2Latest Papers from Table of Contents or Articles in PressKonstantinopoulos, P. A., Matulonis, U. A.
The American Association for Cancer Research (AACR)
Published 2018Staff ViewPublication Date: 2018-09-05Publisher: The American Association for Cancer Research (AACR)Print ISSN: 1078-0432Electronic ISSN: 1557-3265Topics: MedicinePublished by: -
3Latest Papers from Table of Contents or Articles in PressTucker, D. W., Getchell, C. R., McCarthy, E. T., Ohman, A. W., Sasamoto, N., Xu, S., Ko, J. Y., Gupta, M., Shafrir, A., Medina, J. E., Lee, J. J., Mac; Donald, L. A., Malik, A., Hasselblatt, K. T., Li, W., Zhang, H., Kaplan, S. J., Murphy, G. F., Hirsch, M. S., Liu, J. F., Matulonis, U. A., Terry, K. L., Lian, C. G., Dinulescu, D. M.
The American Association for Cancer Research (AACR)
Published 2018Staff ViewPublication Date: 2018-03-16Publisher: The American Association for Cancer Research (AACR)Print ISSN: 1078-0432Electronic ISSN: 1557-3265Topics: MedicinePublished by: -
4Articles: DFG German National LicensesBurstein, H. J. ; Ramirez, M. J. ; Petros, W. P. ; Clarke, K. D. ; Warmuth, M. A. ; Marcom, P. K. ; Matulonis, U. A. ; Parker, L. M. ; Harris, L. N. ; Winer, E. P.
Springer
Published 1999Staff ViewISSN: 1569-8041Keywords: Doxil ; metastatic breast cancer ; phase I ; vinorelbineSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Background: Vinorelbine and Doxil (liposomal doxorubicin) are active chemotherapeutic agents in metastatic breast cancer. A phase I study was designed to evaluate combination therapy. Patients and methods: Thirty women with metastatic breast cancer were enrolled. Dose-limiting toxicity was determined through a dose escalation scheme, and defined for the first treatment cycle, only. Pharmacokinetic studies were performed during the first cycle of treatment. Results: In the first cohort of Doxil 30 mg/m2 day 1 and vinorelbine 25 mg/m2 days 1 and 8, patients experienced severe neutropenia. Vinorelbine administration was changed thereafter to days 1 and 15 of each cycle. Dose limiting toxicity was observed at Doxil 50 mg/m2 and vinorelbine 25 mg/m2. Doxil 40 mg/m2 and vinorelbine 30 mg/m2 was defined as the maximally tolerated dose. Few toxicities (principally neutropenia) were seen at this dose level, with the notable absence of significant nausea, vomiting, or alopecia. Though 63% of patients had received prior anthracycline-based chemotherapy, only one patient developed grade 2 cardiac toxicity. Pharmacokinetic studies revealed prolonged exposure to high doxorubicin concentrations for several days following Doxil administration. Conclusions: Combination chemotherapy with Doxil and vinorelbine affords treatment with two active drugs in women with metastatic breast cancer, and appears to have a favorable toxicity profile. A schedule of Doxil 40 mg/m2 day 1 and vinorelbine 30 mg/m2 days 1 and 15 given every 28 days is recommended for phase II studies.Type of Medium: Electronic ResourceURL: